维生素D受体相关LncRNAs在非小细胞肺癌中的应用价值

Application of vitamin D receptor related LncRNAs in non-small cell lung cancer

目的 评估血清维生素D受体(VDR)相关LncRNAs在非小细胞肺癌的诊断和预后中的应用价值。方法 选择2014年1月—2016年1月在本院接受治疗的126例NSCLC患者和90名健康人作为研究对象。研究分为训练集和验证集。训练集纳入20对样本,包括20例NSCLC患者和20例健康对照;验证集包含106例NSCLC患者和70例健康对照。在癌症相关治疗前,收集了所有患者的血清样本,并通过定量逆转录聚合酶链反应测试了4种VDR相关LncRNAs表达情况。通过风险评分分析构建血清LncRNAs诊断模型,并通过接受者工作特征(ROC)曲线分析模型区分NSCLC患者和对照组的诊断效率。结果 在训练集和验证集中,SNHG6、SNHG16、LINC00346和LINC00511在NSCLC和对照样品之间显示出显著的差异表达(P<0.05)。ROC曲线分析显示,当截断值为10.429时,验证集中4个LncRNAs联合的诊断性能更高,AUC为0.824(95%CI:0.754~0.894),灵敏度和特异度分别为93.4%和74.3%。根据风险评分将NSCLC病例分为高风险组(≥10.429)和低风险组(<10.429)。不同风险组在肿瘤分期和淋巴结转移期之间存在明显的差异(P<0.05),并且与低风险组患者相比,高风险组患者表现出明显较低的总体存活率(P<0.05)。结论 4种VDR相关LncRNAs联合应用对NSCLC的诊断具有较高的敏感度和特异度,鉴别诊断准确率较高,并且与患者的不良预后相关。

Objective To evaluate the value of serum vitamin D receptor(VDR)-related LncRNAs in the diagnosis and prognosis of non-small cell lung cancer.Methods 126 patients with NSCLC and 90 healthy people who received treatment in our hospital from January 2014 to January 2016 were selected as the research subjects.The study was divided into the training set and the validation set.The training set included 20 pairs of samples,including 20 NSCLC patients and 20 healthy controls.The validation set included 106 NSCLC patients and 70 healthy controls.Before cancer-related treatment,serum samples of all patients were collected,and the expression of four VDR-related LncRNAs was tested by quantitative reverse transcription polymerase chain reaction.Risk score analysis was performed to construct a serum non-coding RNA diagnostic model for distinguishing NSCLC patients from controls,and ROC curves were then used to evaluate the prediction effect of the profiling.Results In the training set and validation set,SNHG6,SNHG16,LINC00346 and LINC00511 showed significant differential expression between NSCLC and control samples(P<0.05).ROC curve analysis showed that when the cutoff value was 10.429,the diagnostic performance of the four LncRNAs panel in the verification set was higher, with an AUC of 0.824 (95% CI : 0.754~0.894), and the sensitivity and the specificity were 93.4% and 74.3%, respectively. According to the risk score, NSCLC cases were divided into the high-risk group (≥10.429) and the low-risk group (<10.429). There was a significant difference between tumor stage and lymph node metastasis in different risk groups ( P <0.05). Compared with the low-risk group, the high-risk group showed significantly lower overall survival rate ( P <0.05). Conclusion The four VDR-related LncRNAs panel, with the higher sensitivity and specificity and the discriminative accuracy, can serve as a tool for the diagnosis and prognosis in NSCLC.